Pneumococcal pneumonia has been a subject of investigation throughout this century. Early studies established that respiratory tract infection with Streptococcus pneumoniae proceeded from the upper tract to the lungs directly, not via the bloodstream (1, 8, 27, 28) . The events which occur when pneumococci encounter the defense mechanisms of the lungs were examined by Wood and co-workers in a series of experiments beginning 30 years ago (30) (31) (32) (33) (34) (35) . Their findings indicated that pneumococci could be phagocytosed on the alveolar surface in the absence of opsonizing antibody (34) and that pneumococcal capsular polysaccharide inhibited such phagocytosis (33) . Penicillin and sulfonamides, only recently available at that time, were shown to effectively eliminate pneumococci at the advancing edge of experimental pneumonia where bacterial proliferation was rapid but were ineffective against organisms in the more central areas of consolidation (30) (31) (32) 35) . Persistence of pneumococci in the latter areas was attributed to the metabolic inactivity of the organisms, which protected them from the effects of the antimicrobial agents.
Quantitative aspects of lung antibacterial mechanisms were studied by Kass, Green, and co-workers in a series of experiments some years later (14, 15, 26) . Their experiments incorporated several important features: "nonpathogenic" bacteria were used so that defenses could be studied without the confounding variables associated with virulent species; the bacterial challenge was delivered by aerosol rather than by intrabronchial instillation, to distribute organisms evenly within the lung; quantitative methods were used throughout; and sophisticated statistical techniques were applied in evaluating the results (26) . With this approach it was shown that the lung is capable of inactivating enormous numbers of bacteria within a few hours. The rate of bacterial activation was independent of the number of organisms deposited within a range of 103 to 105 organisms per lung, and only about 10% of the initial inoculum remained viable 4 h after aerosol exposure (14) . By use of radiolabeled bacteria, it was shown that bacterial inactivation was accomplished predominantly in situ in the lungs (13) , and the alveolar macrophage was identified as the major antibacterial mechanism under these circumstances (10, 15) . Similar techniques have been used by many investigators to show impaired lung antibacterial defenses under a variety of conditions (11, 18, 19, 21, 25) . However, in only rare experiments has the bacterial population of the lung been shown to increase after aerosol challenge, and pneumonia does not ordinarily occur in these models.
Another dimension was added to this technique by Johanson et al., who studied pneumococcal clearance from the lungs of rats with hemorrhagic pulmonary edema caused by hydrochloric acid instillation (22) . Lung bacterial counts increased with time in these animals, suggesting the absence of clearance mechanisms; however, when tetracycline was administered to inhibit bacterial multiplication, clearance still occurred in the presence of hemorrhagic edema, although at a slower rate than in controls. Further, the rate of pneumococcal multiplication increased in animals with edema so that multiplication exceeded clearance, accounting for the increasing bacterial population (22) .
In the present experiments we applied the techniques of Johanson et al. (22) to reexamine the Wood model of pneumococcal pneumonia. Our results indicate that during the early hours ofpneumonia lung defenses are capable of eliminating viable pneumococci rapidly, although not as rapidly as the organisms multiply. However, within 24 At intervals after inoculation, animals were sacrificed by cross-clamping the neck to sublux the cervical spine and to prevent agonal aspiration of oropharyngeal contents. The lungs were removed aseptically and washed in buffer. The lobes were dissected, suspended together in 5 ml of buffer, and homogenized. Initially, the right and left lungs were handled separately, but it became apparent that within 4 h after inoculation equal counts were obtained from both lungs, so this practice was abandoned. Samples of the lung homogenate were serially diluted in buffer, inoculated onto Trypticase soy agar plates containing 5% sheep blood, and incubated for 24 h at 37°C prior to quantitation of pneumococcal colonies. Blood was obtained for culture from either a neck or tail vein. Blood samples were serially diluted and quantitated similarly. Total circulating leukocytes and differential counts were performed on peripheral blood by standard techniques, and the counts were expressed as total polymorphonuclear leukocytes per mm3.
Specimens obtained at intervals after inoculation from some animals were used only for histological examination. The lungs and heart were removed en bloc and fixed inflated with Formalin under 20 cm of hydrostatic pressure. Sections 6 ,um thick were cut, stained with hematoxylin and eosin, and examined by light microscopy.
Tetracycline determinations. Tetracycline is a bacteriostatic antibiotic with no known direct effect on lung defense mechanisms (22) . Its action against S. pneumoniae was investigated by inoculating 10 ml of Todd-Hewitt broths containing various concentrations of tetracycline with 106 log-phase organisms. Minimal inhibitory and bactericidal concentrations were determined by culture after 6 h of incubation at 37°C.
Animals treated with tetracycline received a single injection of tetracycline, 50 mg/kg, intraperitoneally. Subsequent serum levels were measured by the method of Simon and Yin (29) .
The concentration of tetracycline in pneumonic lungs was measured in an additional group of animals with pneumococcal pneumonia. Tetracycline was administered to four animals 12 h after onset of infection and to three animals 24 h after onset of infection. Six hours after tetracycline administration, the lungs were removed. Sections of lung, including separate portions of atelectatic and consolidated lung, were dissected aseptically, weighed, and homogenized in 5 ml of buffer. The concentration of tetracycline in lung homogenates and simultaneous serum samples was measured with a bioassay technique (29) . Lungs from two infected but untreated animals were assayed as controls.
Studies with PCP. Purified pneumococcal capsular polysaccharide (PCP) obtained from S. pneumoniae, type III, kindly supplied by Francis Tetracycline was administered 12 h after inoculation to one-half of the controls and to all animals receiving PCP. The lungs of all animals were removed and cultured 24 h after pneumococcal inoculation.
Studies with S. epidermidis. Pneumococcal pulmonary infections were produced as above in a group of animals. Twenty-four hours later, 105 S. epidermidis (ATCC 12228) cells, grown to log phase in Trypticase soy broth and resuspended in PBS, were instilled through a tracheotomy into the lungs of the pneumococcus-infected animals and simultaneously into the lungs of a group of uninfected controls. Subsequently, the animals were sacrificed and cultured as previously described.
We studied the effects of PCP on the lung clearance of S. epidermidis in two additional groups of uninfected animals. One group was inoculated with 105 S. epidermidis cells in 0.25 ml of PBS, and the second group received 105 S. epidermidis cells mixed with 0.3 mg of PCP in 0.25 ml of PBS. The lungs of all animals were removed and cultured 6 h after inoculation.
Differences between control and experimental groups in each experiment were evaluated with Student's t test for unpaired data. Probabilities equal to or less than 0.05 were considered significant.
RESULTS
Characteristics of the model of pneumococcal pneumonia. Animals inoculated intrabron-
chially with 104 pneumococci consistently developed a progressive pulmonary infection. The number of pneumococci cultured from the lungs of these animals at various intervals after inoculation is shown in Fig. 1 . Pneumococcal counts increased from 104 organisms inoculated at zero time to 6 x 107 organisms at 48 h.
Blood cultures demonstrated bacteremia with quantitative counts increasing from 102 organisms/ml at 12 h to 104 organisms/ml at 48 h ( Fig. 1) . At these levels, the number of organisms in the blood could not have contributed significantly to the number of pneumococci cultured from the lungs. Although the mean total polymorphonuclear leukocyte counts were increased at 24 and 36 h, individual animals varied widely, and there was no significant difference in counts between 0 and 24 h (P > 0.05) or between 0 and 36 h (P > 0.1) (Fig. 1) . Sporadic deaths began occurring at 24 h, and most untreated animals died within 72 h.
The gross and microscopic findings in the lungs 12 h after inoculation were usually normal, although occasional mild atelectatic and congestive changes were noted. At 24 h, the lungs had extensive atelectasis, often with grossly visible consolidation and pleuropericarditis. Atelectasis was manifested by erythematous, small lungs which returned to a normal gross appearance when fully inflated with either air or fixative. Bacterial counts were similar in lungs demonstrating atelectasis, consolidation, or both. Representative microscopic sections of an area of consolidation in a 24-h infection are shown in Fig. 2 and 3 .
The lungs of animals sacrificed 48 h after inoculation had changes similar to those found at 24 h, although consolidation was usually more extensive.
Effect of tetracycline on pneumococcal clearance in pneumococcal pneumonia. The increasing pulmonary bacterial population in untreated animals ( Fig. 1) clearly indicates that pneumococci multiplied faster than they could be cleared by pulmonary antibacterial defenses. The capacity of lung defenses to kill pneumococci may be directly assessed if bacterial multiplication can be inhibited. To ensure that bacteriostatic levels of tetracycline were achieved, serum and lung concentrations were measured after the intraperitoneal injection of 50 mg/kg of body weight. The mean serum tetracycline concentration was 9.8 ug/ml at 4 h, 1.8 gm/ml at 6 h, and not detectable at 12 h.
The concentration of tetracycline in pneumonic lungs 6 h after injection averaged 10.3 ,ug/g (8, 10, 10, and 13 ,g/g) in animals with 12-h infections and 12.7 ug/g (12, 12, and 14 ,ug/g) in animals with 24-h infections. Concentrations of tetracycline between 1 and 20 ug/ml were bacteriostatic over a 6-h period of incubation in vitro; higher concentrations were bactericidal.
The effects of tetracycline on the course of infection with S. pneumoniae, type III, are shown in Fig. 4 . When administered 1 h prior to pneumococcal inoculation, or 4 to 12 h after inoculation, tetracycline was associated with rapid disappearance of viable pneumococci (Fig. 4) . Since the drug is only bacteriostatic, this finding indicates the preservation of effective antipneumococcal mechanisms in the lungs of these animals as late as 12 h after onset of infection. In contrast to the rapid killing of the pneumococci which occurred when tetracycline was given within 12 h of infection, bacterial killing did not occur if tetracycline administration was delayed until 24 h after pneumococcal inoculation (Fig. 5) . A transient decrease in lung bacterial counts occurred 4 h after tetracycline, but by 48 h after the onset of infection the numbers of pneumococci were the same in tetracycline-treated animals and controls. This observation suggests that the bactericidal capacity of the lung became markedly impaired during the course ofthe pneumococcal infection.
An alternative explanation for our data could be that the bacterial population of the lungs at 
22-3 pneumococcal inoculation (A---), 4 h after inoculation (U---U), or 12 h after inoculation (0-0---). Each
group consisted of six to eight animals. Vertical bars show the mean ± the standard error of the mean.
VOL. 17, 1977 24 h, 107 organisms, is too large for even intact defense mechanisms to handle. This possibility was studied by inoculating additional animals with 107 S. pneumoniae cells; such animals pretreated with tetracycline rapidly cleared an inoculum of 107 log-phase pneumococci (Fig. 6) . Effect of PCP on the clearance of pneumococci. PCP is known to accumulate in pneumonic lungs and is produced by the pneumococcus in excess during logarithmic growth (33) . Studies were done to determine whether the addition of PCP to the initial inoculum of 104 S. pneumoniae cells would impair bacterial killing in the presence of tetracycline. The results of this experiment (Fig. 7) show that PCP caused a dose-related inhibition of antipneumococcal defenses. The addition of 0.038 mg of PCP produced no impairment of pneumococcal killing, whereas with amounts of 0.3 mg or greater lung bacterial killing was markedly reduced and lung bacterial counts were similar to those in animals not receiving tetracycline.
S. epidermidis clearance. The specificity of the impairment in host defenses associated with pneumococcal pneumonia and the administration of PCP was studied with S. epidermidis. S. epidermidis was cleared at a similarly rapid rate from the lungs of animals with a 24-h pneumococcal pneumonia and from the lungs of controls (Fig. 8) . The addition of 0.3 mg of PCP to the inoculum did not alter the clearance ofS. epidermidis in uninfected animals, compared with controls (Fig. 9) .
DISCUSSION
There are four important features in the data presented. First, the ability ofthe lung to eliminate viable pneumococci after intrabronchial instillation is inversely related to inoculum size. Second, lung antipneumococcal defenses are capable of inactivating enonnous numbers of pneumococci in the early hours after infection, although they cannot keep pace with bacterial multiplication. Third, the capacity for pneumococcal inactivation ceases 24 h after infection. Fourth, this acquired defect in host defenses does not extend to other bacterial species and appears to be due to the accumulation of pneumococcal capsular material in the lung.
The rate of inactivation of inhaled bacteria appears to be largely independent of inoculum size (13) , in contrast to our findings with the intrabronchial bolus model. This difference may not seem surprising at first. However, the evenly distributed deposition of 106 bacteria in the rat lung by aerosol and our deposition of 104 bacteria in 0.05 ml of fluid would result in similar numbers of bacteria per unit of lung volume since the functional residual capacity of the rat lung is about 5.0 ml (17) . Further, we demonstrated that as many as 107 bacteria in 0.05 ml were rapidly killed, if bacterial multiplication was prevented. This latter finding also suggests that the fluid bolus itself did not significantly impair phagocytosis and killing. On the basis of available data, it is not clear why viable pneumococci deposited in the lung by aerosol are rapidly eliminated (22) , whereas those deposited by intrabronchial bolus produce a progressive infection.
Our data do emphasize the urgent requirement for swift phagocytosis of organisms capable of rapid multiplication in the lungs, such as the pneumococcus. About 50% of staphylococci deposited in the lung by an aerosol challenge are phagocytosed by the end of a 30-min expo- sure period, and 80% are phagocytosed within 1 h (14) . This response involves only alveolar macrophages. Phagocytosis of bacteria in the alveolar spaces of a nonnal lung does not require opsonization by specific antibody. The role of nonspecific opsonins is less clear. Intracellular killing of staphylococci by alveolar macrophages is enhanced by prior contact of the organism with the lipid fraction of the alveolar lining fluid, although the rate of bacterial ingestion is not affected (20, 24) . In contrast to the response of the lung to aerosolized staphylococci, the intrabronchial deposition of type m S. pneumoniae causes a rapid recruitment of circulating polymorphonuclear leukocytes into the lung (34) . Since alveolar edema precedes infiltration of the lung by polymorphonuclear leukocytes in the development of pneumococcal pneumonia (12) , it is reasonable to believe that plasma proteins are present in greater concentrations in such areas of the lung than in normal alveolar spaces. Effective opsonization of many pneumococcal types is mediated nonspecifically by the alternate complement pathway, allowing rapid phagocytosis and killing by polymorphonuclear leukocytes (2, 7) . However, type III pneumococci, as well as types IV and VIII, do not activate the alternate pathway unless specific antibody is present, and type I pneumococci do not appear to activate complement in either the presence or absence of antibody (7) . Although the role of these interactions in defense of the lung against pneumococcal infection has not been clearly demonstrated, it is intriguing to speculate that the lack of nonspecific opsonization of these capsular types may underlie their propensity to cause pneumonia in humans.
The administration of an antimicrobial agent in our study, as in those of Wood and co-workers (30) (31) (32) 35) , had no effect on the course ofthe pneumococcal infection once the latter had been established for as long as 24 h. Wood et al. attributed the lack of antimicrobial effectiveness to the metabolic inactivity of microorganisms in the central portions of the pneumonia (31) . Our findings suggest instead that the persistence of viable bacteria in the presence of tetracycline is due to a failure of lung antibacterial mechanisms. These two factors may well coexist. To support our conclusion, it was necessary to show that tetracycline was not bactericidal in our model system and that effective concentrations of tetracycline were achieved in the areas of lung consolidation. After the intraperitoneal injection of tetracycline, 50 mg/kg, peak serum concentrations of 9.8 ,ig/ml occurred after 4 h. The concentrations of tetracycline in pneumonic lungs, determined 2 h after achievement of peak serum levels, were 10 ,ug/g in animals treated 12 h after onset of infection and 13 ug/g in animals treated 24 h after infection. Tetracycline was bacteriostatic in vitro at concentrations as high as 20 ug/ml. Thus, tetracycline was present in similar, bacteriostatic concentrations in the pneumonic lung at 12 and 24 h, and the observed differences in bacterial elimination at these times can be attributed to the development of an impairment in host antipneumococcal defenses.
Despite the marked depression of antipneumococcal defenses associated with the development of pneumonia, the capacity of the lung to inactivate staphylococci was not impaired. only some bacterial species (16) . These findings suggest that the inability of the pneumonic lung to kill pneumococci is due to the development of a selective defect and is not due only to edema, atelectasis, or other nonspecific mechanisms. The addition of PCP to the infecting inoculum mimicked pneumonia in that it markedly impaired pneumococcal clearance but did not affect the inactivation on staphylococci. The inhibitory effect of PCP on pneumococcal clearance was dose related; maximal inhibition occurred with the addition of 0.3 mg of PCP. This amount is small in comparison to the quantity of PCP found in the lungs of humans dying of pneumococcal pneumonia (9) . The presence of detectable concentrations of PCP in the blood or urine of patients with pneumococcal pneumonia has been associated with azotemia (4), empyema (4), bacteremia (6, 23) , and death (3, 6) . The presence of large amounts of PCP in sputum of patients with type III pneumococcal pneumonia also has been associated with severe infection and increased mortality (9) . However, in human infections it is not clear whether demonstrable increases in PCP cause more severe disease or are the result of it (5). Our results suggest that the accumulation of PCP in the lungs during the early hours of type IHl pneumococcal pneumonia inhibits bacterial phagocytosis and killing and is an important contributing factor in the pathogenesis of this infection.
